Table 4 Results for conditional logit model for eliciting the public preferences for pharmaceutical subsidy in Iran
Attribute | Level | β (SE) | P-value | Relative importance (percentage) |
|---|---|---|---|---|
Survival | Low (one year) | 0.156 (0.051) |  < 0.05 | 34.1 |
Average (5 years) | 0.878 (0.051) |  < 0.05 | ||
High (10 years) | 1.245 (0.053) |  < 0.05 | ||
Quality of life | Low (15%) | 0.447 (0.047) |  < 0.05 | 26.6 |
Average (30%) | 0.668 (0.053) |  < 0.05 | ||
High (50%) | 0.862 (0.047) |  < 0.05 | ||
Alternative treatment | No | 0.451 (0.029) |  < 0.05 | 22.6 |
Age group | 18–60 years | 0.051(0.044) | 0.245 | 7.8 |
Older than 60 years | \(-\) 0.477 (0.047) |  < 0.05 | ||
All age groups | 0.273 (0.050) |  < 0.05 | ||
Cost to government | Average (100 million IRR or 2380 US dollar) | 0.071 (0.050) | 0.160 | 4.1 |
High (500 million IRR or 11,900 US dollar) | \(-\)0.140 (0.050) |  < 0.05 | ||
Disease severity | Moderate | \(-\)0.064 (0.038) | 0.095 | 4.8 |
Severe | \(-\)0.143 (0.043) |  < 0.05 | ||
Drug manufacturer country | Domestic production | \(-\)0.061 (0.045) | 0.181 | 0 |
Goodness of fit | LR Chi2[15] | 1601.910 | ||
Log likelihood | − 4274.270 | |||
Pseudo-R2 | 0.157 | |||
Number of observations | 14,644 | |||